MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial

Trial Profile

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Interferon beta-1b (Primary) ; Lopinavir/ritonavir (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Therapeutic Use
  • Acronyms MIRACLE
  • Most Recent Events

    • 02 Nov 2017 Planned number of patients changed from 80 to 194.
    • 28 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 30 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top